Biotech Values

[biomaven0]

>>I'm not saying TRIL shareholders should be biting their fingernails on this point.

Antigenicity far down my list of potential concerns for TRIL. I'd guess neutralizing antibodies even if they developed (for which there is zero evidence) wouldn't prove insuperable - I would think you could just increase the dose some. That's the great thing about an on-target DLT - any loss in potency can be overcome by increased dosing.

Of course if you start combining with CTLA4 drugs or the like who knows what might happen.

The main concern here (as with all the CD47 drugs) is pretty much all efficacy - we still lack robust proof of that.